We See A
World of Vibrant
Possibilities
We See
New Ways to
Healthier Vision
We See the
Brilliance of
Science
We Are Graybug
We See You
“We believe that no patient should have to settle for good enough. We are curious and focused on finding practical solutions that make a real difference.”
“Our passion is to help people with vision-threatening diseases live fuller, more vibrant lives through healthier vision. That’s why we come to work every day.”
“The power of science means nothing until you see the impact it can have on people’s lives. Our work starts with listening to the people we serve the ophthalmologists and their patients.”
“Our singular focus is to deliver transformative medicines for the treatment of chronic diseases of the retina and optic nerve, and we do it in partnership with them.”
Sight is our most precious sense. At Graybug Vision, we believe that the world should be a place of brilliance, clarity, light and hope. We See You!
What We Solve for
For people with chronic diseases of the retina and the optic nerve, we develop medicines that make healthy vision more accessible and manageable, promoting better compliance and visual outcomes.
What We Solve for
“What we experience in everyday practice are patients failing to return for their regular injections or coming back when the disease has already caused irreversible damage to their retina. Some patients will even drop out of treatment completely. Graybug’s science may be able to address this unmet need.”
David Boyer, MD
Retina-Vitreous Associates Medical Group
Adjunct Clinical Professor at University of Southern California/Keck School of Medicine
What We Solve for
“I’m excited about Graybug’s technology which is designed for the sustained delivery of pharmacologic agents to the eye. It has the potential to improve real world outcomes of patients with retinal diseases by reducing their treatment burden.”
Arshad Khanani, MD
Director of Clinical Research, Sierra Eye Associates
Clinical Associate Professor at the University of Nevada, Reno School of Medicine
Our Pipeline
Based on our proprietary technologies, our R&D pipeline targets a range of chronic vision-threatening diseases, such as wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, as well as primary open angle glaucoma.
GB-102
We are developing GB-102 as a twice-per-year intravitreal pan-VEGF inhibitor for the treatment of wet AMD and DME.
GB-103
We are developing GB-103 as a once-per-year intravitreal pan-VEGF inhibitor for the treatment of diabetic retinopathy.
GB-401
We are developing GB-401 as a twice-per-year intravitreal beta-blocker for the treatment of primary open angle glaucoma.
We Are Graybug
We are a clinical stage biopharmaceutical company founded in 2011 on the basis of technology licensed from the Johns Hopkins School of Medicine. We are focused on developing transformative medicines that help people with chronic vision-threatening diseases of the retina and the optic nerve.